EPS for Johnson & Johnson (JNJ) Expected At $2.03

September 15, 2018 - By Christine McCrea

Johnson & Johnson (NYSE:JNJ) LogoInvestors sentiment increased to 0.97 in Q2 2018. Its up 0.04, from 0.93 in 2018Q1. It is positive, as 36 investors sold Johnson & Johnson shares while 806 reduced holdings. 114 funds opened positions while 704 raised stakes. 1.84 billion shares or 8.07% more from 1.71 billion shares in 2018Q1 were reported.
Teachers Retirement Systems Of The State Of Kentucky stated it has 458,128 shares or 0.66% of all its holdings. Ameritas Invest Prtnrs holds 0.4% or 68,094 shares. Moreover, Family Firm Inc has 0.26% invested in Johnson & Johnson (NYSE:JNJ). Ontario Teachers Pension Plan Board holds 0.68% or 405,089 shares. Fincl Bank Of The Ozarks accumulated 17,770 shares. Rice Hall James And Assocs Ltd Company owns 29,441 shares for 0.13% of their portfolio. The Pennsylvania-based Hbk Sorce Advisory Limited Liability Company has invested 0.65% in Johnson & Johnson (NYSE:JNJ). Sky Invest Grp Inc Limited Co reported 65,685 shares or 3.22% of all its holdings. Blue Financial reported 20,499 shares. Lagoda Mngmt Limited Partnership reported 43,325 shares. Balyasny Asset Management Ltd Company holds 12,619 shares. Atria Invests Ltd Liability Corporation holds 54,298 shares or 0.29% of its portfolio. Baker Avenue Asset Mngmt L P has 0.5% invested in Johnson & Johnson (NYSE:JNJ). 24,785 are owned by Holt Cap Limited Com Dba Holt Cap Prtn L P. California-based Guardian Inv Mgmt has invested 3.56% in Johnson & Johnson (NYSE:JNJ).

Since August 27, 2018, it had 0 insider purchases, and 2 insider sales for $4.99 million activity. 7,899 shares were sold by Kapusta Ronald A, worth $1.08M on Friday, September 7.

Analysts expect Johnson & Johnson (NYSE:JNJ) to report $2.03 EPS on October, 16.They anticipate $0.13 EPS change or 6.84 % from last quarter’s $1.9 EPS. JNJ’s profit would be $5.45 billion giving it 17.18 P/E if the $2.03 EPS is correct. After having $2.10 EPS previously, Johnson & Johnson’s analysts see -3.33 % EPS growth. The stock decreased 0.29% or $0.4 during the last trading session, reaching $139.49. About 4.53M shares traded. Johnson & Johnson (NYSE:JNJ) has risen 5.07% since September 15, 2017 and is uptrending. It has underperformed by 10.55% the S&P500.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 9 analysts covering Johnson & Johnson (NYSE:JNJ), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Johnson & Johnson had 13 analyst reports since March 23, 2018 according to SRatingsIntel. Goldman Sachs upgraded the shares of JNJ in report on Thursday, July 12 to “Neutral” rating. The rating was maintained by Credit Suisse with “Outperform” on Friday, April 20. The firm has “Buy” rating by Credit Suisse given on Tuesday, June 12. The firm has “Buy” rating given on Wednesday, April 18 by Leerink Swann. The company was maintained on Friday, April 13 by Jefferies. The stock of Johnson & Johnson (NYSE:JNJ) earned “Hold” rating by Stifel Nicolaus on Wednesday, April 18. Credit Suisse upgraded it to “Buy” rating and $15400 target in Thursday, April 12 report. Wells Fargo maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, April 18. Wells Fargo has “Buy” rating and $15000 target. On Wednesday, April 18 the stock rating was maintained by Deutsche Bank with “Buy”. The firm has “Buy” rating given on Friday, March 23 by Jefferies.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $374.22 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 277.32 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Seekingalpha.com which released: “Johnson & Johnson (JNJ) Management Presents at Barclays Global Consumer Staples Conference Call (Transcript)” on September 06, 2018, also Seekingalpha.com with their article: “Breakout Alert: Buy Johnson & Johnson” published on August 20, 2018, Seekingalpha.com published: “Johnson & Johnson: Where Is The Path To Gains?” on September 11, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Trump Insurance For Johnson & Johnson” published on August 17, 2018 as well as Seekingalpha.com‘s news article titled: “J&J working on India hip compensation” with publication date: September 07, 2018.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.